Rubella Diagnostic Testing Market Report 2026

The rubella diagnostic testing market size has grown strongly in recent years. It will grow from $1.39 billion in 2025 to $1.48 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to expansion of routine viral screening programs, increased awareness of congenital rubella syndrome, availability of serological testing kits, growth in diagnostic laboratory networks, adoption of immunoassay technologies.

The rubella diagnostic testing market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing investments in advanced diagnostic platforms, rising focus on maternal health screening, expansion of automated laboratory testing, growing adoption of point-of-care diagnostics, strengthening of infectious disease surveillance systems. Major trends in the forecast period include increasing adoption of molecular diagnostic techniques, rising use of pcr-based rubella testing, growing demand for prenatal screening, expansion of high-sensitivity immunoassays, enhanced focus on early disease detection.

The increasing incidence of viral infections is expected to drive the growth of the rubella diagnostic testing market in the coming years. Viral infections are illnesses caused by viruses, which are tiny infectious agents that can only replicate within the living cells of an organism. The rise in viral infections is influenced by factors such as increased global travel, which facilitates cross-border virus transmission, and climate change, which alters vector habitats and expands the range of disease-carrying organisms. Rubella diagnostic testing enables early identification and management of rubella infections, helping to prevent complications - particularly in pregnant women - and supporting outbreak control to limit virus spread. For example, in December 2023, the National Health Service, a UK-based government department, reported that daily hospital admissions for flu averaged 234, reflecting a 53% increase from the previous week, while hospital cases of norovirus rose by 15% to an average of 406 daily, representing a 28% increase compared with the same week the previous year. Therefore, the rising incidence of viral infections is driving the growth of the rubella diagnostic testing market.

Leading companies in the rubella diagnostic testing market are focusing on innovative solutions, such as rubella virus vaccines, to improve diagnostic accuracy and preventive measures. Rubella vaccines provide immunity against the virus and are often administered as part of the MMR or MMRV combination vaccines to prevent rubella and its associated complications. For instance, in March 2023, Merck & Co., Inc., a US-based pharmaceutical company, received FDA approval for the intramuscular (IM) administration of its M-M-R II vaccine, which protects against rubella, measles, and mumps. This approval enables healthcare providers to administer the rubella vaccine via the IM route, aligning with other routinely recommended pediatric vaccines. Vaccination against rubella is critical for preventing outbreaks and protecting against severe complications, especially in pregnant women.

In September 2024, Leinco Technologies Inc., a US-based developer of high-purity antibodies, acquired QED Biosciences for an undisclosed sum. This acquisition enables Leinco Technologies to expand its antibody product portfolio and development services, enhancing its capabilities in life sciences and in vitro diagnostics while supporting its growth strategy and commitment to innovation and quality for global researchers. QED Biosciences, based in the US, develops novel monoclonal and polyclonal antibody products and provides rubella diagnostic testing services.

Major companies operating in the rubella diagnostic testing market are Cardinal Health Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, bioMérieux S.A., Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics Inc., DiaSorin S.p.A., Meridian Bioscience Inc., Fortress Diagnostics Ltd., Mylab Discovery Solutions Pvt. Ltd., MP Biomedicals LLC, CTK Biotech Inc., ZEUS Scientific Inc., Creative Diagnostics, Arlington Scientific Inc., AccuBioTech Co. Ltd., Intec Products Inc., Vitrosens Biotechnology Ltd., Sprint Diagnostics Pvt. Ltd., InDevR Inc., Atlas Medical GmbH.

North America was the largest region in the rubella diagnostic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rubella diagnostic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rubella diagnostic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the rubella diagnostic testing market by increasing costs of imported reagents, diagnostic instruments, assay kits, and laboratory automation components. Diagnostic laboratories in North America and Europe are most affected due to dependence on imported testing materials, while Asia-Pacific faces pricing pressure on exported diagnostic kits. These tariffs are raising testing costs and influencing procurement cycles. However, they are also encouraging domestic reagent production, localized diagnostic manufacturing, and increased investment in regional laboratory infrastructure.

The rubella diagnostic testing market research report is one of a series of new reports that provides rubella diagnostic testing market statistics, including rubella diagnostic testing industry global market size, regional shares, competitors with a rubella diagnostic testing market share, detailed rubella diagnostic testing market segments, market trends and opportunities, and any further data you may need to thrive in the rubella diagnostic testing industry. This rubella diagnostic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rubella diagnostic testing refers to the methods used to detect the rubella virus or antibodies in a patient’s blood, helping determine whether they have been infected with rubella or possess immunity. These tests enable healthcare providers to accurately diagnose rubella and manage its implications, particularly in vulnerable populations.

The main types of diagnostic techniques in rubella testing include latex agglutination, liver function tests, enzyme immunoassay (EIA), radioimmunoassay (RIA), fluorescent immunoassay (FIA), and others. Latex agglutination is a method where tiny latex beads coated with rubella-specific antigens or antibodies are combined with a patient’s sample. This technique is used across various age groups, including neonates, teenagers, and adults, and serves multiple end users such as hospitals, clinics, cancer diagnostic centers, ambulatory surgical centers, and others.

The rubella diagnostic testing market consists of revenues earned by entities by providing services such as serological testing services, serologic tests, molecular diagnostic services, and rapid diagnostic testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The rubella diagnostic testing market also includes sales of serological assays, IgM antibodies, rapid diagnostic tests (RDTs), and polymerase chain reaction (PCR) tests. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.